We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Kedrion Biopharma has started the development of a plasma-derived therapy for treating the COVID-19 virus that could make it available to patients in as little as three to six months.